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Abstract
We have reported that transgenic mice overexpressing rat apo
E shows marked reduction of plasma cholesterol and triglycer-
ide levels due to the disappearance ofVLDL and LDL. In this
study, we investigated the metabolism ofplasma lipoproteins in
transgenic mice. After intravenous injection, the rates of clear-
ance of '25I-VLDL and '25I-LDL were 3.0- and 2.4-fold greater
in transgenic mice than in controls, respectively. Furthermore,
clearance of chylomicron remnants estimated by oral retinyl
palmitate-loading test was markedly enhanced in transgenic
mice. The hepatic expression ofLDL receptors by immunoblot
analysis was similar in both groups. These data suggest that
elimination of lipoproteins containing apo B was due to en-
hanced clearance of these lipoproteins enriched with apo E
through hepatic LDL receptors. When fed a high cholesterol
diet, controls showed twofold elevation of plasma cholesterol
levels with marked increases in VLDL and LDL cholesterol on
gel filtration chromatography. In contrast, cholesterol-fed
transgenic mice showed resistance against these increases.
High cholesterol feeding decreased the activity of hepatic LDL
receptors and had no effect on enhancement of chylomicron
remnant clearance in transgenic mice. Thus, overexpression of
apo E facilitates metabolism of lipoproteins containing apo B
presumably primarily via the LDL receptor pathway and possi-
bly through an interaction with the chylomicron remnant recep-
tor. (J. Clin. Invest. 1992.90:2084-2091.) Key words: choles-
terol * very low density lipoprotein * low density lipoprotein.
chylomicron remnants * low density lipoprotein receptor
Introduction
Apo E is mainly produced in the liver and is a major constitu-
ent ofmammalian lipoproteins. This protein, along with apo B
100, functions in the metabolism of plasma lipoproteins
through its interaction with the LDL receptor mainly in the
liver (for reviews see references 1, 2). Apo E is also thought to
be a specific ligand for a putative hepatic chylomicron remnant
receptor and to be involved in the metabolism of intestinal
lipoproteins ( 1, 2). Furthermore, apo E is expressed in many
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other tissues and plays a crucial role in the transport and redis-
tribution oflipids in peripheral tissues such as brain, peripheral
nerves, and the arterial wall ( 1, 3, 4). Several lines ofevidence
suggest that lipoproteins containing several molecules ofapo E
have higher affinity for LDL receptors than those without apo
E ( 1, 5-7). In vitro studies have demonstrated that VLDL
particles enriched with apo E by exogenous addition or gene
transfection of apo E are taken up efficiently by cultured cells
(8-1 1 ). In vivo studies have also shown that lipoproteins with
apo E are more rapidly removed from plasma than those with-
out apo E ( 12-14). Recently, we and another group have re-
ported that intravenous administration of apo E lowered
plasma cholesterol level in hypercholesterolemic rabbits due to
enhanced clearance ofVLDL ( 15, 16). These findings suggest
that apo E functions in determining the metabolic fate of lipo-
proteins containing apo B 100. To further investigate the role of
apo E in vivo, we have established lines oftransgenic mice with
high plasma levels ofapo E, which is overproduced in the liver
under the control of the metallothionein promoter ( 17). Ho-
mozygotes for line 4-20, the highest liver expressor, exhibited a
marked reduction in plasma cholesterol and triglyceride levels,
with elimination of VLDL and a marked decrease in LDL
( 18 ). They also showed resistance against diet-induced hyper-
cholesterolemia ( 18). In the present study, we investigated the
mechanism by which overexpression of apo E caused these
dramatic decreases in plasma lipoproteins containing apo B in
transgenic mice. The kinetic studies of plasma lipoproteins in
these animals demonstrated that overexpression ofapo E mark-
edly enhanced plasma turnover ofVLDL, LDL, and chylomi-
cron remnants through interactions with the receptors possess-
ing high affinity for apo E.
Methods
Materials. Na 1251, '25I-protein A, [a32P]dCTP, and Ly32p]ATP were
purchased from New England Nuclear/Dupont (Boston, MA). BSA,
TCA, PMSF, and Triton X-100 were obtained from Sigma Chemical
Co. (St. Louis, MO). All reagents used were ofanalytical grade. BDFl
mice were from Nippon Bio-supply Center (Tokyo, Japan). cDNA
probes for mouse LDL receptor related protein and rat apo B were
kindly donated by Dr. J. Herz and Dr. A. Matsumoto, respectively.
Animals. Transgenic mice that overexpress rat apo E under the
control of the metallothionein promoter, line 4-20, were established as
described previously (17). Homozygous line 4-20 aged 16-20 wk were
used in this study. In some experiments, heterozygotes were also used.
Sibling mice that lacked the transgene or normal mice with the same
genetic background ([C57BL6 x BDAJ F2 hybrids) and of the same
age were used as controls. These animals were maintained on normal
chow and given water supplemented with 20 mM ZnSO4 for > 2 wk to
induce the expression of rat apo E from the transgene. For cholesterol
feeding, some groups ofthe mice were fed a diet containing 1% choles-
terol and 0.5% deoxycholate for 2 wk. For determination of plasma
2084 Shimano, Yamada, Katsuki, Yamamoto, Gotoda, Harada, Shimada, and Yazaki
J. Clin. Invest.
© The American Society for Clinical Investigation, Inc.
0021-9738/92/11/2084/08 $2.00
Volume 90, November 1992, 2084-2091
cholesterol levels, blood was drawn from retroorbital plexus after a
12-h fast. In some experiments, animals were anesthetized with pento-
barbital and killed for resection ofthe liver. After blood was drawn by
cardiac puncture, small aliquots of livers were immediately used or
frozen at -80'C until use for preparation of plasma membrane frac-
tion or total RNA or extraction of lipids.
Analyses. Plasma cholesterol levels were determined by a commer-
cial kit using the cholesterol oxidase method ( 19). Analysis of choles-
terol in plasma lipoprotein classes was conducted by gel filtration chro-
matography (HPLC) using TSK G3000SW (Tosoh Co., Tokyo, Ja-
pan) and Superose 6 HR (Pharmacia LKB Biotechnology, Uppsala,
Sweden) as previously described ( 18).
Retinyl palmitate-loading test. After a 4-h fast, the animals were
orally administered 2 mg (for mice fed a normal diet) and 0.5 mg (for
mice fed a cholesterol diet) of retinyl palmitate in an aqueous form
dissolved in 18% castor oil (Chocola A; Eisai Co., Ltd., Tokyo, Japan)
orally through a gastric cannula. Blood samples were drawn before and
at 0.5, 1, 2, 4, and 8 h after loading. During the experiment, the animals
were fasted with access to water ad lib. The animals tolerated the load-
ing well without symptoms ofmalabsorption, such as diarrhea. Venous
blood was drawn from the retroorbital plexus and transferred to a tube
containing sodium EDTA. Samples (- 50-100 ,l) were immediately
centrifuged and plasma was stored wrapped in foil at -20'C before
retinyl palmitate assay.
Retinyl palmitate assay. The pooled plasma samples were diluted
to 0.2 ml with saline and mixed with 1 ml ofwater and 1 ml ofethanol.
The mixture was mixed vigorously with 5 ml of hexane containing
0.05% BHT. The hexane phase (4 ml) was separated by centrifugation
at 1,000 rpm for 5 min and evaporated to dryness under nitrogen. The
residue was dissolved in 100 Al of isopropanol, and an aliquot was
injected into the HPLC column (Nucleosil C18; Nargel, Diren, Ger-
many). Ethanol/water (95:5) was used as the mobile phase at a flow
rate of 0.5 ml/min. The column effluent was monitored fluorometri-
cally with E. at 330 nm and Em at 480 nm. The peaks of retinol and
retinyl palmitate were identified by comparison to the retention times
of respective purified standards. The amounts of retinol and retinyl
palmitate were determined by proportional comparison of the peak
heights of samples and standards.
Lipoproteins and iodination. Blood was drawn and pooled from 10
control mice and 10 heterozygous mice by cardiac puncture. Fresh
plasma was separated with I mg/ml disodium EDTA, 0.2 mg/ml so-
dium azide, and 300 ,g/ml benzamidine. To separate VLDL, interme-
diate density lipoprotein (IDL)', LDL, and HDL, plasma was ultracen-
trifuged in a rotor (model 40.3; Beckman Instruments, Fullerton, CA)
at 38,000 rpm at 12°C at the sequential KBr densities of 1.006, 1.019,
1.063, and 1.21 for 16, 18, 20, and 48 h, respectively (20). The floated
lipoproteins were dialyzed against 150mM NaCl, 2 mM sodium phos-
phate, pH 7.4, 0.1 mg/ml EDTA, and 0.2 mg/ml sodium azide.
VLDL, LDL, and HDL were iodinated with '25I by the method of
McFarlane (21 ) with slight modification. After removal of free iodine
on a column of Sephadex G 50 (PD 10; Pharmacia Inc., Piscataway,
NJ), the iodinated lipoproteins were dialyzed against S liters of the
same buffer with four exchanges and finally against the same buffer
without EDTA and sodium azide.
Kinetic studies. lodinated lipoproteins (250-500 MCi/ 100 ul per
animal) were injected into mice as a bolus via the tail vein. Blood was
taken 1 min after the injection as zero time and at the specified times by
puncture of the retroorbital plexus. Plasma (30 Ml) was isolated from
each blood sample. For the kinetic studies ofVLDL and LDL, plasma
was diluted to 0.5 ml with saline containing human LDL (0.5 mg
protein/ml) as carrier, followed by addition of0.5 ml isopropanol, and
was kept at room temperature for 1 h to precipitate apo B. The mixture
was centrifuged at 13,000 rpm for 10 min in a microfuge tube (22).
The radioactivities in the mixture and half volume of the supernatant
1. Abbreviations used in this paper: IDL, intermediate density lipopro-
tein; LRP, LDL receptor-related proteins.
were counted with a gamma counter. The apo B radioactivity was cal-
culated as follows: apo B radioactivity in pellet (cpm) = total plasma
radioactivity (cpm) - radioactivity in supernatant (cpm). Forthe turn-
over studies ofHDL, plasma was diluted to 0.5 ml with saline contain-
ing 1 mg/ml BSA, followed by addition of 0.1 ml 50% TCA. After
centrifugation, the count ofthe precipitate in 10% TCA was measured.
The removal rate of each lipoprotein was calculated from the plasma
disappearance curve by the method of Matthews (23).
Immunoblot analysis for hepatic LDL receptor. The immunoblot
was performed as previously described (24). All ofthe following proce-
dures were carried out in an ice box. An aliquot ofliver ( 1 g) in 40 ml of
ice-cold buffer containing the following (mM); 150 NaCl, 10 TrisHCI,
1 CaC12, and 1 PMSF, pH 8.0 was minced and homogenized with
Polytron at the setting of 5 for 20 s (Kinematica GmbH, Littau, Swit-
zerland). From the liver homogenates, membrane pellets (8,000-
100,000-g pellets) were prepared according to Kovanen's method (25).
The resultant pellets were rapidly frozen at -80'C before use. The
membrane pellet was resuspended in lysis buffer containing 50 mM
Tris-maleate, 2 mM CaCl2, 1% Triton X-100, and 1 mM PMSF, pH
6.5. The protein content of each lysate was measured with a BCA (bi-
cinchoninic acid) protein assay kit (Pierce Chemical Co., Rockford,
IL). Each sample containing 200 jg ofprotein was adjusted to 1% SDS,
50 mM TrisHCl, pH 6.8, 10% glycerol, and 0.1% bromphenol blue,
without heating or adding reducing agent. The samples were then sub-
jected to SDS-PAGE (7% gel) at 10 mA at4C for 12 h according to the
method ofLaemmli (26). After electrophoresis, the samples were elec-
trophoretically transferred to nitrocellulose membranes in buffer con-
taining 20mM Trisbase, 150mM glycine, 0.02% SDS, and 20% metha-
nol at 200 mA for 16 h. The sheets were immersed in blocking buffer
containing 150 mM NaCl, 10 mM TrisHCl, pH 7.4, and 50 mg/ml
BSA for 1 h at room temperature and incubated with the same buffer
containing anti-LDL receptor serum, for 24 h at 4°C. Polyclonal anti-
body against rabbit LDL receptor was produced as described previ-
ously (27). The sheets were then washed twice for 15 min with washing
buffer containing 150 mM NaCl, 50 mM TrisHCl, pH 7.4, 0.1% SDS,
0.2% Nonidet P40, and 0.25% deoxycholate and incubated in the
buffer containing '25I-protein A (2,000 cpm/ng, 0.5 ,g/ml) for 5 h at
room temperature. The sheets were washed again, air-dried, and autora-
diographed on x-ray film.
Preparation and analysis of total RNA. Total cellular RNA was
isolated by extraction with acid guanidinium thiocyanate, phenol, and
chloroform as described by Chomczynski and Sacchi (28). Then 15 ,g
of total RNA was subjected to electrophoresis in formaldehyde-agar-
ose (1%) gel, and transferred to a nylon membrane. The filter was
baked, prehybridized, and hybridized as described previously (24) with
the respective labeled probes. The probes used were the 1.55 kbp EcoRI
fragment of rat apo B cDNA (29) and the NotI-XhoI fragment of
mouse LDL receptor-related protein cDNA (30) labeled by random
primer method (31 ) and 5' end-labeled synthetic oligonucleotides that
were the rat apo E-specific sequence (32, 33) and the corresponding
mouse apo E-specific sequence: CCACTGGGGTGATGATGGG.
Determination ofliver content ofesterified and unesterified choles-
terol. Homozygous transgenic mice and control mice fed a normal diet
or high cholesterol diet were anesthetized with pentobarbital and the
liver was resected. A small portion (0.2 g) of liver tissue from each
mouse was homogenized with a Polytron homogenizer in 4 ml ofchlo-
roform/methanol (2:1, vol/vol). Then, 0.2 ml of 50 mM NaCl was
added to 1 ml ofthe mixture, followed by centrifugation. An aliquot of
the organic phase ( 10 Al for determination of total cholesterol content
of liver from cholesterol-fed mice, 50 ,l for other samples) was evapo-
rated under nitrogen. The residual lipids were used for determination
ofesterified and unesterified cholesterol content using commercial kits.
Results
Expression ofapo E and plasma cholesterol levels. Homozy-
gotes for transgenic line 4-20 harboring the metallothionein
promoter-rat apo E fusion gene were maintained on water con-
Lipoprotein Metabolism in Apolipoprotein E Transgenic Mice 2085
rvmw aM piobe-
o APG
! 0,SP(r rr~
18S- mouse
rat aPoE-4 * * apoE - *
Figure 1. Northern blot analysis of livers from transgenic mice using
oligonucleotide probes specific to rat apo E and mouse apo E. All
animals were given water containing 20 mM ZnSO4 to induce ex-
pression of the transgene. Hepatic total RNA ( 15 ug) from homozy-
gous (homo) and heterozygous (hetero) rat apo E transgenic mice
was separated by agarose gel electrophoresis, transferred to a nylon
membrane, and hybridized with differential oligosynthetic probes
specific for rat apo E or mouse apo E. Hepatic RNA from Wister rat
and nontransgenic mouse was also analyzed as respective controls.
taining zinc sulfate to induce the expression of the transgene.
Fig. 1 shows Northern blot analyses using differential specific
probes for rat and mouse apo E mRNAs. Rat apo E mRNA
level in the liver of homozygotes was twice that of heterozy-
gotes, indicating that both integrated genes were expressed in
homozygotes. This mRNA level in homozygotes is almost as
high as that in rats. The levels of mouse endogenous apo E
mRNA in the transgenic lines were equivalent to that of con-
trols, suggesting that expression of the transgene has no effect
on endogenous expression of mouse apo E. Thus, it was con-
firmed that the effect of rat apo E from the transgene product
should be additive to that of endogenous mouse apo E.
Plashna cholesterol levels were compared with those of nor-
mal control mice with the same genetic background. Com-
High-Choleterol Diet
Controls Heterozygots
pared with controls (89.8±11.5 mg/dl, n = 20) homozygotes
showed a 60% decrease in plasma cholesterol level (36.1± 11.9
mg/dl, n = 20), which was greater than that previously re-
ported in six homozygous mice (43%) (18). Heterozygotes
showed an intermediate level (69.8±18.5 mg/dl, n = 20).
When control mice were fed a high cholesterol diet containing
1% cholesterol and 0.5% deoxycholate for 14 d, plasma choles-
terol levels were elevated to 191±41.4 mg/dl (n = 20). In con-
trast, homozygous and heterozygous transgenic mice showed a
level of 83.4±17.7 mg/dl and 125±37.1 mg/dl, respectively (n
= 20).
These data are consistent with previously reported results
in a small number of animals ( 18 ). Fig. 2 shows the profile of
plasma lipoprotein cholesterol by gel filtration chromatogra-
phy in high cholesterol-fed mice. Controls fed a normal diet
showed three peaks ofVLDL, LDL, and HDL. In the previous
study, disappearance of VLDL and a marked (80%) decrease
in LDL were observed in homozygous transgenic mice ( 18).
Compared with controls on a normal diet, cholesterol-fed con-
trols showed a large and steep peak ofVLDL and a broad peak
composed ofLDL and probably IDL, indicating that the rise in
plasma cholesterol levels was caused by increases in cholesterol
contents of lipoproteins containing apo B. In contrast, the in-
creases in VLDL and LDL cholesterols in homozygotes were
much smaller and were similar to those of controls fed a nor-
mal diet. Heterozygotes showed intermediate levels of both
classes. There was no difference in HDL cholesterol levels
among the three groups, although these values were slightly
lower than that of controls fed a normal diet.
Plasma turnover oflipoproteins. To study the clearances of
plasma lipoproteins in the transgenic lines, kinetic studies of
each lipoprotein class were performed (Fig. 3). Because homo-
zygotes have an undetectable level ofplasma VLDL and a very
low level of LDL, it was very difficult to separate sufficient
amounts ofVLDL and LDL from homozygotes to conduct the
turnover studies. We therefore obtained each class of lipopro-
tein from the plasma of 10 heterozygotes. Respective lipopro-
teins were iodinated and injected into homozygotes. lodinated
Normal Diet
Homozygotes Controls
0.02
E
-6
,cI0.
20 30 40
HMDL
40 20 30 40 20 30
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Figure 2. Profile of plasma lipoprotein
cholesterol by gel filtration chromatogra-
phy in cholesterol-fed transgenic mice. Ho-
mozygous and heterozygous transgenic
mice and non-transgenic control mice were
maintained on a high cholesterol diet and
water containing 20 mM ZnSO4 for 14 d.
A 10-zd sample of pooled fasting plasma
from each group was applied to an HPLC
system composed ofTSK G3000SW and
Superose 6 HR as described in Methods.
Plasma cholesterol level of each group is
shown in the text. The peak positions of
VLDL, LDL, and HDL are indicated. IDL
cholesterol may be between VLDL and
LDL peaks in cholesterol-fed mice. The
profile of plasma from control mice on a
normal diet is also shown for comparison.
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controls. The removal rates in transgenic and control mice
were 23.1± 1.4 and 7.8±0.5 pools/d (n = 3), respectively. As
shown in Fig. 3 B, 125I-LDL was also removed 2.4-fold faster in
the transgenic mice than in controls (removal rates: 8.3±1.8 vs.
3.4±0.1 pools/d, n = 3). In contrast, the clearance of 1251-HDL
was not significantly different between the two groups, espe-
cially in the time interval shortly after injection (Fig. 3 C).
Retinyl palmitate-loading test. The retinyl palmitate toler-
ance test was conducted to investigate plasma turnover ofchy-
lomicron remnants in homozygous and heterozygous trans-
genic lines and controls (Fig. 4 A). No retinyl palmitate was
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Figure 3. Plasma turnover of lipoproteins in transgenic mice. (A)
VLDL, (B) LDL, (C) HDL. Each lipoprotein class was prepared from
plasma samples from 10 zinc-induced heterozygous transgenic mice
and nontransgenic controls. Each lipoprotein fraction from heterozy-
gotes and controls was labeled with 125I and injected intravenously
via the tail vein into other sets (n = 3) of homozygotes and controls,
respectively ('25I-VLDL, '25I-LDL, 25Q MCi/animal; 1251-HDL, 500
uCi/animal). At specified times, plasma samples were taken. For the
kinetic studies of '251-VLDL and '251I-LDL, the percentage of injected
radioiodine in apo B was measured. For the kinetic study of '251-HDL,
the percentage of injected TCA-precipitable radioiodine was mea-
sured. The values are expressed as mean±SE% (n = 3, bars; where
not shown, SE values fall within data points. closed circle, transgenic
mice; open circle, controls). The first plasma sample was obtained
1 min after injection and was used to set the value at zero time. The
recovery of radioiodine in apo B at zero time calculated from body
weight was > 90% of total injected radioiodine in apo B in each ani-
mal. The percent apo B in counts of injected 125I-VLDL from trans-
genic and control mice was 50 and 55%, respectively. The percent apo
B of injected '251I-LDL was 60% in both groups.
lipoproteins prepared from 10 normal control mice were in-
jected into another set of control animals. Fig. 3 A shows
plasma disappearances of '25I-VLDL. The clearance of VLDL
was markedly accelerated in transgenic mice compared with
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Figure 4. Plasma retinyl palmitate levels in transgenic mice on a (A)
normal diet and (B) high cholesterol diet after oral administration.
Aqueous retinyl palmitate (2 mg for animals on a normal diet, 0.5
mg for high cholesterol-fed animals) was orally administered to ho-
mozygous and heterozygous transgenic mice and controls (n = 3).
At specified times, blood was taken. Plasma samples were separated,
pooled, and the levels of retinyl palmitate and retinol ('4g/dl) were
determined by HPLC as described in Methods (closed circle, homo-
zygotes; closed triangle, heterozygotes; open circle, controls). For the
animals on a normal diet, the values are mean±SE (tg/dl) from three
independent experiments (bars; where not shown, SE values fall
within data points.).
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Figure 5. Plasma retinol levels in transgenic mice after oral adminis-
tration. Free retinol levels (Ag/dl) were measured in pooled plasma
samples from animals on a normal diet after oral retinyl palmitate-
loading test as described in Fig. 4. (closed circle, homozygotes; closed
triangle, heterozygotes; open circle, controls)
detected before the oral challenge in any animal. A peak of
plasma retinyl palmitate level was observed at 2 h after loading
in controls. At each time point, the mean plasma retinyl palmi-
tate level was highest in controls, intermediate in heterozy-
gotes, and lowest in homozygotes. For both peak height and
area under the curve, the values in homozygotes were < 20% of
those in controls. To evaluate intestinal absorption and hepatic
uptake of the administered retinyl palmitate, the changes in
plasma free retinol levels were also compared between groups
(Fig. 5). Unlike retinyl palmitate, considerable levels of
plasma retinol were detectable before loading in controls, het-
erozygotes, and homozygotes in descending order of magni-
tude. Each group showed a sluggish peak at 2 h after oral admin-
istration of retinyl palmitate. The peak area for homozygotes
was 80% of that of controls and heterozygotes had a similar
area to controls. The clearance of chylomicron remnants in
each group after high cholesterol feeding was also assessed by
retinyl palmitate-loading test (Fig. 4 B). Cholesterol-fed ho-
mozygotes showed higher clearance than cholesterol-fed con-
trols to the same degree as observed on a normal diet. In one
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Figure 6. Immunoblot analysis of hepatic LDL receptor proteins in
transgenic mice fed a normal and a high cholesterol diet. Plasma
membranes (200 ,g protein) prepared from the livers of each group
(n = 2) were electrophoresed on 7% SDS polyacrylamide gel and
electrophoretically transferred to a nitrocellulose membrane. The
membrane was incubated with anti-rabbit LDL receptor antibody,
sequentially with '25I-protein A, and autoradiographed. Molecular
mass standards are indicated.
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Figure 7. Northern blot analysis of hepatic LRP mRNA from trans-
genic mice on a normal and a high cholesterol diet. Total RNA (15
Mg) prepared from the livers of each group (n = 2) was subjected to
Northern blot analysis using cDNA probe for LRP.
cholesterol-fed homozygous mouse, no plasma retinyl palmi-
tate was detected at any time point with this method.
Hepatic LDL receptors by immunoblot and mRNA level of
LRP. The enhanced clearance oflipoproteins containing apo B
may be attributable to increased LDL receptor activity in the
transgenic lines. To test this possibility, hepatic LDL receptors
were compared on immunoblot analysis. As shown in Fig. 6,
hepatic LDL receptors ofhomozygotes and controls had equiv-
alent protein level. After cholesterol feeding, expression ofthe
receptors was decreased in both groups and no significant dif-
ference was found between both groups. This result suggests
that LDL receptor activity is not involved in the lower plasma
levels oflipoproteins containing apo B in transgenic mice com-
pared with controls. mRNA levels of LDL receptor-related
proteins (LRP) were also compared (Fig. 7). There were no
significant differences between the two groups and no consis-
tent changes when a high cholesterol diet was fed.
Esterified and unesterified cholesterol contents in the livers.
As shown in Table I, the major proportion of liver cholesterol
was unesterified in mice fed on a normal diet. There was no
significant difference in esterified and free cholesterol content
between control and transgenic mice. High cholesterol feeding
caused a marked increase in liver content of esterified choles-
terol in both groups with a similar degree of magnitude, sug-
gesting that dietary cholesterol was absorbed into the liver in
both groups.
Expression of apo B. Blot hybridization analysis of liver
RNA with apo B cDNA probe is shown in Fig. 8. No significant
difference was found in apo B mRNA levels between homozy-
gotes and controls. After high cholesterol feeding, a slight (den-
sitometrically 1.4-fold) increase in apo B expression was ob-
served in both groups. To analyze the relative amounts of two
apo B molecules, apo B100 and apo B48, aliquots of VLDL
Table I. Cholesterol Contents in Livers
Normal diet High cholesterol diet
Control Transgenic Control Transgenic
Unesterified 2.4±0.10 2.3±0.09 2.4±1.0 2.6±0.15
Esterified 1.2±0.50 1.6±0.51 9.5±0.47 11.0+1.3
Livers were resected from homozygous transgenic mice and non-
transgenic controls on a normal diet and on a high cholesterol diet.
After lipid extraction, esterified and unesterified cholesterol contents
were measured. Values were expressed as mean±SE mg/g tissue
(n = 3).
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and LDL obtained for turnover studies were subjected to elec-
trophoresis on SDS polyacrylamide gel (Fig. 9). VLDL sepa-
rated from controls contained a higher level of apo B48 (with
an apparent molecular mass of 260 kD) than apo B100 (550
kD). VLDL from heterozygotes possessed almost equal
amounts of apo B48 and apo B100. LDL from both groups
contained a greater amount of apo B100 than apo B48. The
ratios of apo B48 to apo B100 in control VLDL, transgenic
VLDL, control LDL, and transgenic LDL by a densitometric
scan were 2.0, 1.0, 0.5, and 0.3, respectively.
Discussion
The present study clarified the mechanism of the marked re-
duction of lipoproteins containing apo B in transgenic mice
overexpressing apo E. Kinetic studies demonstrated that
VLDL is cleared markedly faster in homozygotes than in con-
trols. In particular, in the initial phase (the first hour) the accel-
eration was remarkable, contributing to an efficient plasma
removal ofVLDL in transgenic mice. In our previous study, we
observed that rat apo E molecules from the transgene were
distributed among all lipoprotein classes (18). Therefore,
VLDL particles in transgenic lines were enriched with rat apo E
and acquired higher affinity for the LDL receptor, resulting in
enhanced uptake presumably primarily by the liver. The clear-
ance ofVLDL in homozygotes was so rapid that these particles
were eliminated from the circulation. This is consistent with
the in vitro data that the cultured cells secreting rat apo E take
up VLDL in the medium more efficiently than control cells in
the study of CHO cells transfected with a plasmid containing
the fusion gene used in this study ( 11). Interestingly, when
'251-labeled human VLDL was injected, the turnover was very
similar among controls and heterozygous and homozygous
transgenic mice (data not shown). The data suggest that the
transfer ofapo E between lipoproteins in plasma is not so rapid
and that enrichment of VLDL with apo E in transgenic mice
might occur rather locally in the liver. SDS-PAGE showed that
mouse VLDL contains both apo BI00 and apo B48, and that
the ratio of apo B48 to apo B100 in VLDL in heterozygotes is
lower than in controls, suggesting more rapid clearance of
VLDL containing apo B48 than VLDL containing apo BI00
when enriched with apo E. Furthermore, the turnover ofLDL
was also faster in transgenic mice than in controls. Unlike hu-
man LDL, a considerable proportion ofplasma apo E was dis-
tributed on LDL in normal and transgenic mice (control: 17%,
heterozygotes: 19%, and homozygotes: 9%) (18). At a rough
estimate from apparent molecular masses of apo E and apo B,
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Figure 8. Northern blot analysis of hepatic apo B mRNA from
transgenic mice on a normal and a high cholesterol diet. Total RNA
( 15 ug) prepared from the livers of each group (n = 2) was subjected
to Northern blot analysis using cDNA probe for apo B.
VLDL LDL Figure 9. Apo Bl00 and apo
Cont Tg Cont Tg B48 on VLDL and LDL from
550 kQD _ _ transgenic mice. VLDL and
LDL were prepared from het-
200kD erozygous transgenic mice and
controls. Aliquots ofthese li-
poproteins (10 ,g protein of VLDL, 50 ug protein of LDL) were
electrophoresed on SDS-polyacrylamide gel (3-10% gradient). The
gel was stained with Coomassie brilliant blue. The ratio ofapo B48
to apo B100 in the text was calculated from their intensities by den-
sitometric scan. Molecular mass standards are indicated.
numbers ofapo E molecules on both VLDL and LDL particles
were increased approximately fourfold in heterozygous trans-
genic mice compared with respective controls. These addi-
tional apo E molecules on LDL particles may increase their
affinity for the LDL receptor, as observed with VLDL. Thus,
the decrease in LDL cholesterol in homozygotes is attributed
not only to decreased lipolytic conversion from VLDL that has
disappeared from plasma, but also to enhanced clearance of
LDL enriched with apo E. Since transgenic mice have the same
LDL receptor activity as controls (Fig. 6), enhanced clearance
ofVLDL and LDL in transgenic mice is likely due to increased
affinity of these lipoproteins for the LDL receptor. It was re-
ported that homozygotes and heterozygotes represented 80 and
50% decreases in plasma apo B levels, respectively, compared
with controls ( 18). Considering that the current kinetic studies
were performed by injection ofVLDL and LDL prepared from
heterozygotes into homozygotes, the 3.0- and 2.4-fold increases
in the respective removal rates ofVLDL and LDL can account
for the decreases in plasma apo B levels and hence the reduc-
tion in plasma lipoproteins containing apo B in transgenic
mice. From the VLDL apo B levels in VLDL used for the
kinetic study, it was estimated that the calculated synthetic
rates ofVLDL apo B in controls and transgenic mice were 10.6
and 11.8 mg/kg body wt per d, respectively. The similar pro-
duction rates of VLDL apo B are consistent with the similar
levels of hepatic apo B mRNA (Fig. 8). On the other hand,
there were no significant differences in the kinetics of HDL
between the two groups. This is consistent with the observation
that homozygotes showed only a slight decrease in HDL choles-
terol level.
In addition to VLDL and LDL, the retinyl palmitate-load-
ing test demonstrated that overexpression of apo E caused a
profound and dose-dependent effect on the metabolism ofchy-
lomicron remnants. The retinyl palmitate methodology as a
specific marker for chylomicron and chylomicron remnants
has been under some criticism in human studies because a
considerable portion of plasma retinyl palmitate can be trans-
ferred to denser lipoproteins, especially in the late phase of the
loading test (34). However, the transfer would be negligible in
the present study because mice lack cholesteryl ester transfer
protein activity (35). It is theoretically possible that decreased
plasma levels of retinyl palmitate in transgenic mice may be
due to decreased intestinal absorption of retinyl palmitate.
However, this improbable theory can be excluded by the results
of plasma free retinol levels. After intestinal absorption, dietary
retinoids are incorporated into chylomicrons, taken up by the
liver via the portal circulation, and stored in the liver as retinyl
esters. Some retinyl esters in the liver are hydrolyzed and reti-
nol is secreted into the circulation in a bound form with reti-
nol-binding protein (for review see reference 36). Thus, in a
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physiological state, there is a considerable stable level of retinol
in plasma, whereas retinyl palmitate is undetectable by com-
mon techniques. Therefore, the peak in the plasma level of
retinol after retinyl palmitate loading reflects intestinal absorp-
tion and hepatic uptake ofdietary retinyl palmitate. The peaks
of plasma retinol levels in transgenic lines were comparable to
that in controls, suggesting that similar amounts of challenged
retinyl palmitate were absorbed in intestines and carried to the
livers in each group. Since intestinal expression of apo E is
minimal in the transgenic line used in this study ( 17), nascent
chylomicrons produced in the intestines should be devoid of
apo E. It has been reported that chylomicrons incubated with
apo E are taken up more efficiently by the perfused liver from
an estradiol-treated rat (6, 37). The present study is the first
report that hepatic overexpression ofapo E enhances clearance
of chylomicron remnants in vivo, although the lower baseline
level of plasma triglycerides in transgenic mice in itself might
have a minimal effect on the plasma clearance of retinyl palmi-
tate. In their conversion to remnants, chylomicrons are sup-
posed to acquire rat apo E molecules somewhere in circulation
in the transgenic line. Interestingly, microscopic examination
after immunohistochemical staining demonstrated high stain-
ing for rat apo E from the transgene in the sinusoidal area ofthe
liver in homozygotes (unpublished observation), as observed
in rat liver (38). Abundant apo E molecules in these areas may
be involved in the hepatic uptake of chylomicron remnants
trapped in the space of Disse. The identification of receptor(s)
responsible for uptake ofchylomicron remnants enriched with
apo E is conflicting. The similar results of the retinyl palmi-
tate-loading test in transgenic mice on a normal diet and a high
cholesterol diet, which showed decreased LDL receptor activ-
ity, suggest considerable involvement of a putative chylomi-
cron remnant receptor. Supporting this, it was reported that
clearance ofchylomicron remnants in LDL receptor deficiency
is normal in the retinyl palmitate-loading test on the patients
with familial hypercholesterolemia (39). Meanwhile, it was re-
ported that the LDL receptor plays a large role in the clearance
of chylomicron remnants in rats from study of the effect of
injection of anti-LDL receptor antibody (40).
Cholesterol feeding caused a marked increase in lipopro-
teins containing apo B in normal mice (Fig. 2). The marked
increase in liver cholesterol content (Table I) and slight in-
crease in apo B mRNA level (Fig. 8) suggest that the increase in
plasma cholesterol is due to increases of both cholesterol con-
tent and number of these particles. In rodents, both apo B 100
and apo B48 seem to be produced in the liver (41 ) and it was
reported that the apo B48 content was relatively increased
rather than the apo B100 content when fed a high cholesterol
diet (42). Because apo B48 has no affinity for LDL receptors,
cholesterol-rich lipoproteins containing apo B48 would accu-
mulate in the circulation ofcholesterol-fed control mice unless
an appropriate number ofapo E molecules were present on the
particles, even if residual LDL receptors were still active.
Transgenic mice on a high cholesterol diet also showed high
cholesterol contents in the liver, indicating that dietary choles-
terol was absorbed and finally carried to the liver as well as in
cholesterol-fed controls. Thus, it is likely that transgenic mice
also synthesize as much cholesterol-rich lipoproteins as con-
trols. However, additional apo E from the transgene could facil-
itate clearance ofcholesterol-rich lipoprotein particles via resid-
ual LDL receptors and counterbalance increased production of
cholesterol-rich lipoproteins, resulting in resistance against hy-
percholesterolemia. In transgenic mice, the total cholesterol
influx into the liver would be similar to that in controls receiv-
ing either a normal or high cholesterol diet because the low
plasma levels and the high efficient uptake oflipoproteins con-
taining apo B would be balanced. This explains why transgenic
and control mice have similar amounts of liver cholesterol, as
observed in transgenic mice overexpressing LDL receptor (43)
and similar LDL receptor activity on either diet in the steady
states.
The clearances ofthese cholesterol-rich lipoproteins in cho-
lesterol-fed mice appears to be via the LDL receptor pathway
because the expression of LDL receptor protein was not com-
pletely suppressed. However, it is difficult to determine the
contribution of the chylomicron remnant receptor exactly, es-
pecially in the clearance of lipoproteins containing apo B in
cholesterol-fed transgenic mice. LRP (30), a candidate for
the apo E receptor, can take up fVLDL enriched with apo E
(44, 45). Plasma VLDL particles in cholesterol-fed transgenic
mice are likely to be similar to jVLDL or cholesterol-rich chy-
lomicron remnants and are likely to be cleared via LRP. On a
high cholesterol diet, expression of LRP was not suppressed in
both transgenic and control mice (Fig. 7) (44), whereas he-
patic LDL receptors were decreased. It is possible that relative
contribution of LRP to the clearance of lipoproteins contain-
ing B48 may be greater when these lipoproteins are enriched
with cholesterol and apo E.
Many of the observations in apo E transgenic mice, such as
marked reduction in lipoproteins containing apo B and resis-
tance against diet-induced hypercholesterolemia, were very
similar to those in transgenic mice overexpressing LDL recep-
tor (43, 46). This is not surprising since the two transgenic
lines represent the augmentation of the same interaction be-
tween the ligand and the receptor by overexpression of either.
However, there are expected to be also some distinctions be-
tween the two lines because another ligand or apo B100, and
another receptor or chylomicron remnant receptor, would also
be involved in lipoprotein metabolism. To assess the quantita-
tive role of the chylomicron remnant receptor, which may be
LRP, further studies are required using a manipulation to to-
tally suppress the LDL receptor in the apo E transgenic line,
such as by combination with gene targeting of LDL receptor.
In the current study, it was found that overexpression of
apo E has a profound effect on clearance of lipoproteins con-
taining apo B48 and apo B100, and plays a crucial role in
regulation of the metabolism of these lipoproteins. Increased
plasma apo E levels are frequently observed in hyperlipidemic
patients and animals. Increased production of apo E may be a
compensatory reaction to clear high plasma levels of lipids,
although in humans the plasma apo E level even if increased
may be insufficient to decrease plasma lipids in hyperlipidemic
patients. The present data also suggest that exogenous adminis-
tration of apo E may be of therapeutic benefit to patients with
hyperlipidemia and atheroma.
Acknowledgments
We are very grateful to Dr. M. S. Brown and Dr. J. L. Goldstein for a
helpful discussion.
This work was supported by a grant for diabetes research from
Otsuka Pharmaceutical Co., Ltd. (Tokushima, Japan).
2090 Shimano, Yamada, Katsuki, Yamamoto, Gotoda, Harada, Shimada, and Yazaki
References
1. Mahley, R. W. 1988. Apolipoprotein E: cholesterol transport protein with
expanding role in cell biology. Science (Wash. DC). 240:622-630.
2. Brown, M. S., and J. L. Goldstein. 1986. A receptor pathway for cholesterol
homeostasis. Science (Wash. DC). 232:34-37.
3. Elshourbagy, N. A., W. S. Liao, R. W. Mahley, and J. M. Taylor. 1985.
Apolipoprotein E mRNA is abundant in the brain and adrenals, as well as in the
liver, and is present in other tissues of rats and marmosets. Proc. Nail. Acad. Sci.
USA. 82:203-207.
4. Ignatius, M. J., E. M. Shooter, R. E. Pitas, and R. W. Mahley. 1987.
Lipoprotein uptake by neuronal growth cones in vitro. Science (Wash. DC).
236:959-962.
5. Pitas, R. E., T. L. Innerarity, K. S. Arnold, and R. W. Mahley. 1979. Rate
and equilibrium constants for binding of apo-E HDLc (a cholesterol-induced
lipoprotein) and low density lipoproteins to human fibroblasts: evidence for mul-
tiple receptor binding ofapo-E HDLc. Proc. Nail. Acad. Sci. USA. 76:2311-2315.
6. Windier, E., Y. Chao, and R. J. Havel. 1980. Regulation of the hepatic
uptake of triglyceride-rich lipoproteins in the rat. J. Biol. Chem. 255:8303-8307.
7. Windier, E. E. T., P. T. Kovanen, Y. Chao, M. S. Brown, R. J. Havel, andJ.
L. Goldstein. 1980. The estradiol-stimulated lipoprotein receptor of rat liver. A
binding site that mediates the uptake of rat lipoproteins containing apoproteins B
and E. J. Biol. Chem. 255:10464-10471.
8. Eisenberg, S., G. Friedman, and T. Vogel. 1988. Enhanced metabolism of
normolipidemic human plasma very low density lipoprotein in cultured cells by
exogenous apolipoprotein-3. Arteriosclerosis. 8:480-487.
9. Ishibashi, S., N. Yamada, H. Shimano, N. Mori, H. Mokuno, T. Gotoda,
M. Kawakami, T. Murase, and F. Takaku. 1990. Apolipoprotein E and lipopro-
tein lipase secreted from human monocyte-derived macrophages modulate very
low density lipoprotein uptake. J. Biol. Chem. 265:3040-3047.
10. Mokuno, H., N. Yamada, H. Shimano, S. Ishibashi, N. Mori, K. Takaha-
shi, T. Oka, T. H. Yoon, and F. Takaku. 1991. The enhanced cellular uptake of
very-low-density lipoprotein enriched in apolipoprotein E. Biochim. Biophys.
Acta. 1082:63-70.
11. Shimano, H., C. Fukazawa, Y. Shibasaki, N. Mori, T. Gotoda, K. Harada,
M. Shimada, N. Yamada, Y. Yazaki, and F. Takaku. The effect ofapo Esecretion
on lipoprotein uptake in transfected cells. Biochim. Biophys. Acta. 1086:245-
254.
12. Yamada, N., D. M. Shames, J. B. Stoudmire, and R. J. Havel. 1986.
Metabolism of lipoproteins containing apolipoprotein B-100 in blood plasma of
rabbits: heterogeneity related to the presence of apolipoprotein E. Proc. Nat.
Acad. Sci. USA. 83:3479-3483.
13. Yamada, N., D. M. Shames, and R. J. Havel. 1987. Effect of low density
lipoprotein receptor deficiency on the metabolism of apolipoprotein B-100 in
blood plasma. J. Clin. Invest. 80:507-515.
14. Yamada, N., D. M. Shames, K. Takahashi, and R. J. Havel. 1988. Metabo-
lism of apolipoprotein B-100 in large very low density lipoproteins of blood
plasma. J. Clin. Invest. 82:2106-2113.
15. Yamada, N., H. Shimano, H. Mokuno, S. Ishibashi, T. Gotohda, M.
Kawakami, Y. Watanabe, Y. Akanuma, T. Murase, and F. Takaku. 1989. In-
creased clearance of plasma cholesterol after injection of apolipoprotein E into
Watanabe heritable hyperlipidemic rabbits. Proc. Natl. Acad. Sci. USA. 86:665-
669.
16. Mahley, R. W., K. H. Weisgraber, M. M. Hussain, B. Greenman, M.
Fisher, T. Vogel, and M. Gorecki. 1989. Intravenous infusion ofapolipoprotein E
accelerates clearance of plasma lipoproteins in rabbits. J. Clin. Invest. 83:2125-
2130.
17. Shimano, H., N. Yamada, M. Shimada, N. Ohsawa, C. Fukazawa, Y.
Yazaki, F. Takaku, and M. Katsuki. 1991. Hepatic and renal expression of rat
apolipoprotein E under control of the metallothionein promotor in transgenic
mice. Biochim. Biophys. Acta. 1090:91-94.
18. Shimano, H., N. Yamada, M. Katsuki, M. Shimada, T. Gotoda, K. Har-
ada, T. Murase, C. Fukazawa, F. Takaku, and Y. Yazaki. 1992. Overexpression
of apolipoprotein E in transgenic mice: a marked reduction in plasma lipopro-
teins except high density lipoprotein, and resistance against diet-induced hyper-
cholesterolemia. Proc. Natl. Acad. Sci. USA. 89:1750-1754.
19. Allain, C. C., L. S. Poon, C. S. G. Chan, W. Richmond, and P. C. Fu. 1974.
Enzymatic determination of total serum cholesterol. Clin. Chem. 20:470-475.
20. Havel, R. J., H. A. Eder, and J. H. Bragdon. 1955. The distribution and
chemical composition of ultracentrifugally separated lipoproteins in human
serum. J. Clin. Invest. 34:1345-1353.
21. McFarlane, A. S. 1958. Efficient trace-labelling of proteins with iodine.
Nature (Lond.). 182:53-54.
22. Yamada, N., and R. J. Havel. 1986. Measurement of apolipoprotein B
radioactivity in whole blood plasma by precipitation with isopropanol. J. Lipid
Res. 27:910-912.
23. Matthews, C. M. E. 1957. The theory of tracer experiments with '3'I-la-
belled plasma proteins. Phys. Med. Biol. 2:36-53.
24. Shimano, H., N. Yamada, S. Ishibashi, K. Harada, A. Matsumoto, N.
Mori, T. Inaba, K. Motoyoshi, H. Itakura, and F. Takaku. 1990. Human mono-
cyte colony-stimulating factor enhances the clearance oflipoproteins containing
apolipoprotein B-100 via both low density lipoprotein receptor-dependent and
-independent pathways in rabbits. J. Biol. Chem. 265:12869-12875.
25. Kovanen, P. T., M. S. Brown, andJ. L. Goldstein. 1979. Increased binding
oflow density lipoprotein to liver membranes from rats treated with 1 7alpha-eth-
inyl estradiol. J. Biol. Chem. 254:11367-11373.
26. Laemmli, U. K. 1970. Cleavage ofstructural proteins during the assembly
of the head of bacteriophage T4. Nature (Lond.). 227:680-685.
27. Shimano, H., H. Aburatani, N. Mori, S. Ishibashi, T. Gotoda, H. Mo-
kuno, M. Kawakami, Y. Akanuma, F. Takaku, T. Murase, etal. 1988. Down-reg-
ulation of hepatic LDL receptor protein and messengerRNA in fasted rabbits. J.
Biochem. 104:712-716.
28. Chomczynski, P., and N. Sacchi. 1987. Single-step method ofRNA isola-
tion by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Bio-
chem. 162:156-159.
29. Matsumoto, A., H. Aburatani, Y. Shibasaki, T. Kodama, F. Takaku, and
H. Itakura. 1987. Cloning and regulation of rat apolipoprotein B mRNA. Bio-
chem. Biophys. Res. Commun. 142:92-99.
30. Hertz, J., U. Hamann, S. Rogne, 0. Myklebost, H. Gausepohl, and K. K.
Stanley. 1988. Surface location and high affinity for calcium of a 500-kd liver
membrane protein closely related to the LDL-receptor suggest a physiological
role as lipoprotein receptor. EMBO (Eur. Mol. Biol. Organ) J. 7:4119-4127.
31. Feinberg, A. P., and B. Vogelstein. 1984. Addendum A technique for
radiolabeling DNA restriction endonuclease fragments to high specific activity.
Anal. Biochem. 137:266-267.
32. Mclean, J. W., C. Fukazawa, and J. M. Taylor. 1983. Rat apolipoprotein E
mRNA. cloning and sequencing of double-stranded cDNA. J. Biol. Chem.
258:8993-9000.
33. Rajavashisth, T. B., J. S. Kaptein, K. L. Reue, and A. J. Lusis. 1985.
Evolution of apolipoprotein E: mouse sequence and evidence for an 1 l-nucleo-
tide ancestral unit. Proc. Natl. Acad. Sci. USA. 82:8085-8089.
34. Krasinski, S. D., J. S. Cohn, R. M. Russel, and E. J. Schaefer. 1990.
Postprandial plasma Vitamin A metabolism in humans: a reassessment ofthe use
ofplasma retinyl esters as markers for intestinally derived chylomicrons and their
remnants. Metabolism. 39:357-365.
35. Agellon, L. B., A. Walsh, T. Hayek, P. Moulin, X. C. Jiang, S. A. She-
lanski, J. L. Breslow, and A. R. Tall. 1991. Reduced high density lipoprotein
cholesterol in human cholesteryl ester transfer protein transgenic mice. J. Biol.
Chem. 266:10796-10801.
36. Blomhoff, R., M. H. Green, T. Berg, and K. R. Norum. 1990. Transport
and storage of vitamin A. Science (Wash. DC). 250:399-404.
37. Windler, E., and R. J. Havel. 1985. Inhibitory effects ofC apolipoproteins
from rats and humans on the uptake of triglyceride-rich lipoproteins and their
remnants by the perfused rat liver. J. Lipid Res. 26:556-565.
38. Hamilton, R. L., J. S. Wong, L. S. S. Guo, S. Krisans, and R. J. Havel.
1990. Apolipoprotein E localization in rat hepatocytes by immunogold labeling
of cryothin sections. J. Lipid Res. 31:1589-1603.
39. Rubinsztein, D. C., J. C. Cohen, G. M. Berger, D. R. van der Westhuyzen,
G. A. Coetzee, and W. Gevers. 1990. Chylomicron remnant clearance from the
plasma is normal in familial hypercholesterolemic homozygotes with defined
receptor defects. J Clin. Invest. 86:1306-1312.
40. Choi, S. Y., L. G. Fong, M. J. Kirven, and A. D. Cooper. 1991. Use ofan
anti-low density lipoprotein receptor antibody to quantify the role of the LDL
receptor in the removal of chylomicron remnants in the mouse in vivo. J. Clin.
Invest. 88:1173-1181.
41. Tennyson, G. E., C. A. Sabatos, K. Higuchi, N. Meglin, and H. B. Brewer,
Jr. 1989. Expression of apolipoprotein B mRNAs encoding higher- and lower-
molecularweight isoproteins in rat liver and intestine. Proc. Natl. Acad. Sci. USA.
86:500-504.
42. Lusis, A. J., B. A. Taylor, D. Quon, S. Zollman, and R. C. LeBoeuf. 1987.
Genetic factors controlling structure and expression ofapolipoprotein B and E in
mice. J. Biol. Chem. 262:7594-7604.
43. Yokode, M., R. E. Hammer, S. Ishibashi, M. S. Brown, and J. L. Gold-
stein. 1990. Diet-induced hypercholesterolemia in mice: prevention by overex-
pression ofLDL receptors. Science (Wash. DC). 250:1273-1275.
44. Kowal, R. C., J. Herz, J. L. Goldstein, V. Esser, and M. S. Brown. 1989.
Low density lipoprotein receptor-related protein mediates uptake of cholesteryl
esters derived from apoprotein E-enriched lipoproteins. Proc. Natl. Acad. Sci.
USA. 86:5810-5814.
45. Lund, H., K. Takahashi, R. L. Hamilton, and R. J. Havel. 1989. Lipopro-
tein binding and endosomal processing ofthe low density lipoprotein receptor-re-
lated protein (LRP) in rat liver. Proc. Natl. Acad. Sci. USA. 86:9318-9322.
46. Hofmann, S. L., D. W. Russell, M. S. Brown, J. L. Goldstein, and R. E.
Hammer. 1988. Overexpression oflow density lipoprotein (LDL) receptor elimi-
nates LDL from plasma in transgenic mice. Science (Wash. DC). 239:1277-
1281.
Lipoprotein Metabolism in Apolipoprotein E Transgenic Mice 2091
